FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2567128295> ?p ?o ?g. }

• W2567128295 abstract "Abstract Abstract 1721 Introduction: CD133 is a transmembrane protein expressed by hematopoietic stem cells and other cell types, whose physiological functions remain unknown. To determine its potential prognostic value in AML, we analyzed its expression on blasts from 76 patients at diagnosis. Moreover, since leukemic stem cells play a critical role in the resistance to chemotherapeutic drugs and may be responsible for relapse, we compared the growth potential and activated cellular pathways of CD133+ and CD133- cells from 20 AML patients. Methods: First, bone marrow samples were collected at diagnosis from 76 AML patients (median age: 65, range: 1–84). CD133 expression was evaluated on blasts cells and CD34+ cells using 6-color flow cytometry (FC) and the monoclonal antibody AC133. The mean fluorescence intensity ratio (MFIR) was calculated by dividing the MFI of CD133 by the MFI of its isotypic control. Second, purified CD34+, CD34+CD133+ and CD34+CD133- cells were isolated from 20 AML bone marrows using the magnetic separation system Minimacs (Miltenyi Biotec). These fractions were submitted to an in vitro colony forming assay during 14 days. Finally, the level of expression of survival proteins involved in the PI3K/AKT, Mitogen-Activated Protein Kinase (MAPK) and Bcl-2 pathways, as well as CXCR4 and Focal Adhesion Kinase (FAK) migration proteins, was analyzed by FC in these fractions. Results: The level of CD133 expression on blasts cells was significantly different between AML patients with favorable (n=12), intermediate (n=38) and unfavorable karyotypes (n=23) (p=0.007). In particular, it was significantly higher in patients with unfavorable karyotype than in patients with intermediate karyotype (p=0.032) or favorable karyotype (p=0.005). Moreover, when considering NPM1 and FLT3 mutation status in patients with intermediate karyotype, the level of CD133 expression was significantly higher in patients with an intermediate molecular profile than in patients with a favorable molecular profile (p=0.004). Most interestingly, we showed that the level of CD133 expression has an impact on overall survival in multivariate analysis, independently of leukocytosis, karyotype and achievement of complete remission after induction therapy (p=0.04). Second, in 20 patients, we found that AML progenitor cells (AML CFU) were present in all sorted fractions, but the CD34+CD133+ fraction gave rise to larger and more numerous colonies (74.9±39.6) than the CD34+CD133- fraction (11,25±6). Moreover, the CD34+CD133+ fraction was the only one able to form secondary colonies (52.1±31.8). Finally, we found that the expression of PI3K (mean percentage of positive cells: 78±20.1), pAKT (80±19.8), pERK (80.1±19), CXCR4 (71.6±22.7), pFAK (81.2±19.8), Bcl-2 (72.9±26.1), Bcl-xL (45.7±24.8), and pBad (63.9±36.1) was significantly upregulated in CD34+CD133+ cells compared to CD34+CD133- cells, whereas Bax was downregulated. Discussion: CD133 is known to be expressed in hematopoietic progenitors, but its role in the resistance to chemotherapy is not well studied. In our work, the level of expression of CD133 on AML blasts appeared as an independent immunophenotypic prognostic factor, encouraging its further evaluation in a larger number of cases. We also showed that CD133+ cells have greater replicative properties than CD133- cells, and exhibit activation of various signaling pathways. Since CD133+ cells might escape from apoptosis through activation of PI3K/AKT and ERK, these proteins could represent potential therapeutic targets. In conclusion, our results revealed that CD133+ cells exhibit more aggressive behavior than CD133- ones, and that CD133+ AML progenitors might contribute to resistance to chemotherapy through preferential activation of PI3K/AKT, MAPK and Bcl-2 survival response. Disclosures: No relevant conflicts of interest to declare." @default.
• W2567128295 created "2017-01-06" @default.
• W2567128295 creator A5005908128 @default.
• W2567128295 creator A5013599527 @default.
• W2567128295 creator A5028495490 @default.
• W2567128295 creator A5045122651 @default.
• W2567128295 creator A5064614311 @default.
• W2567128295 creator A5073168580 @default.
• W2567128295 creator A5089754042 @default.
• W2567128295 creator A5045909277 @default.
• W2567128295 date "2010-11-19" @default.
• W2567128295 modified "2023-09-28" @default.
• W2567128295 title "CD133+ Acute Myeloid Leukemia (AML) Cells Exhibit Higher Clonogenic Capacity and Higher Levels of pAKT and Bcl-2 Proteins Than Their Negative Counterpart" @default.
• W2567128295 doi "https://doi.org/10.1182/blood.v116.21.1721.1721" @default.
• W2567128295 hasPublicationYear "2010" @default.
• W2567128295 type Work @default.
• W2567128295 sameAs 2567128295 @default.
• W2567128295 citedByCount "0" @default.
• W2567128295 crossrefType "journal-article" @default.
• W2567128295 hasAuthorship W2567128295A5005908128 @default.
• W2567128295 hasAuthorship W2567128295A5013599527 @default.
• W2567128295 hasAuthorship W2567128295A5028495490 @default.
• W2567128295 hasAuthorship W2567128295A5045122651 @default.
• W2567128295 hasAuthorship W2567128295A5045909277 @default.
• W2567128295 hasAuthorship W2567128295A5064614311 @default.
• W2567128295 hasAuthorship W2567128295A5073168580 @default.
• W2567128295 hasAuthorship W2567128295A5089754042 @default.
• W2567128295 hasConcept C10205521 @default.
• W2567128295 hasConcept C109159458 @default.
• W2567128295 hasConcept C117262875 @default.
• W2567128295 hasConcept C129470790 @default.
• W2567128295 hasConcept C13373296 @default.
• W2567128295 hasConcept C136302470 @default.
• W2567128295 hasConcept C153911025 @default.
• W2567128295 hasConcept C185592680 @default.
• W2567128295 hasConcept C202751555 @default.
• W2567128295 hasConcept C203014093 @default.
• W2567128295 hasConcept C2778729363 @default.
• W2567128295 hasConcept C2780007613 @default.
• W2567128295 hasConcept C28328180 @default.
• W2567128295 hasConcept C502942594 @default.
• W2567128295 hasConcept C553184892 @default.
• W2567128295 hasConcept C55493867 @default.
• W2567128295 hasConcept C86803240 @default.
• W2567128295 hasConcept C8891405 @default.
• W2567128295 hasConcept C95444343 @default.
• W2567128295 hasConceptScore W2567128295C10205521 @default.
• W2567128295 hasConceptScore W2567128295C109159458 @default.
• W2567128295 hasConceptScore W2567128295C117262875 @default.
• W2567128295 hasConceptScore W2567128295C129470790 @default.
• W2567128295 hasConceptScore W2567128295C13373296 @default.
• W2567128295 hasConceptScore W2567128295C136302470 @default.
• W2567128295 hasConceptScore W2567128295C153911025 @default.
• W2567128295 hasConceptScore W2567128295C185592680 @default.
• W2567128295 hasConceptScore W2567128295C202751555 @default.
• W2567128295 hasConceptScore W2567128295C203014093 @default.
• W2567128295 hasConceptScore W2567128295C2778729363 @default.
• W2567128295 hasConceptScore W2567128295C2780007613 @default.
• W2567128295 hasConceptScore W2567128295C28328180 @default.
• W2567128295 hasConceptScore W2567128295C502942594 @default.
• W2567128295 hasConceptScore W2567128295C553184892 @default.
• W2567128295 hasConceptScore W2567128295C55493867 @default.
• W2567128295 hasConceptScore W2567128295C86803240 @default.
• W2567128295 hasConceptScore W2567128295C8891405 @default.
• W2567128295 hasConceptScore W2567128295C95444343 @default.
• W2567128295 hasLocation W25671282951 @default.
• W2567128295 hasOpenAccess W2567128295 @default.
• W2567128295 hasPrimaryLocation W25671282951 @default.
• W2567128295 hasRelatedWork W104615960 @default.
• W2567128295 hasRelatedWork W1603578230 @default.
• W2567128295 hasRelatedWork W1694703176 @default.
• W2567128295 hasRelatedWork W1762851317 @default.
• W2567128295 hasRelatedWork W2054319577 @default.
• W2567128295 hasRelatedWork W2156234019 @default.
• W2567128295 hasRelatedWork W2331137050 @default.
• W2567128295 hasRelatedWork W2425938725 @default.
• W2567128295 hasRelatedWork W2462874031 @default.
• W2567128295 hasRelatedWork W2552367676 @default.
• W2567128295 hasRelatedWork W2555894919 @default.
• W2567128295 hasRelatedWork W2581552906 @default.
• W2567128295 hasRelatedWork W2588224394 @default.
• W2567128295 hasRelatedWork W2589545036 @default.
• W2567128295 hasRelatedWork W2594213988 @default.
• W2567128295 hasRelatedWork W2969237790 @default.
• W2567128295 hasRelatedWork W2979307109 @default.
• W2567128295 hasRelatedWork W3158809845 @default.
• W2567128295 hasRelatedWork W3210978893 @default.
• W2567128295 hasRelatedWork W740184 @default.
• W2567128295 isParatext "false" @default.
• W2567128295 isRetracted "false" @default.
• W2567128295 magId "2567128295" @default.
• W2567128295 workType "article" @default.